^
    Back
    Association details:
    Biomarker:STK11 mutation
    Cancer:Pituitary Gland Carcinoma
    Drug:temozolomide (DNA synthesis inhibitor) +
    capecitabine (Thymidylate synthase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    CNS Oncol
    Title:

    Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy

    Excerpt:
    Next-generation sequencing revealed an actionable mTOR pathway STK11 mutation in a woman with adrenocorticotropic hormone-secreting pituitary carcinoma refractory to six resections, radiation and CAPecitabine and TEMozolomide.
    DOI:
    10.2217/cns-2016-0011